Jefferies Financial Group Inc. Has $593,000 Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)

Jefferies Financial Group Inc. reduced its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) by 98.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,600 shares of the biopharmaceutical company’s stock after selling 1,176,400 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Cytokinetics were worth $593,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Jones Financial Companies Lllp boosted its holdings in shares of Cytokinetics by 189.8% in the 4th quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 374 shares in the last quarter. Centricity Wealth Management LLC acquired a new position in shares of Cytokinetics in the 4th quarter worth approximately $29,000. AlphaQuest LLC boosted its holdings in shares of Cytokinetics by 113,500.0% in the 4th quarter. AlphaQuest LLC now owns 1,136 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 1,135 shares in the last quarter. J.Safra Asset Management Corp boosted its holdings in shares of Cytokinetics by 62.1% in the 4th quarter. J.Safra Asset Management Corp now owns 1,751 shares of the biopharmaceutical company’s stock worth $83,000 after acquiring an additional 671 shares in the last quarter. Finally, Blue Trust Inc. boosted its holdings in shares of Cytokinetics by 85.8% in the 4th quarter. Blue Trust Inc. now owns 1,823 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 842 shares in the last quarter.

Insider Activity

In other news, EVP Andrew Callos sold 3,341 shares of the business’s stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $43.27, for a total value of $144,565.07. Following the completion of the transaction, the executive vice president now owns 64,434 shares of the company’s stock, valued at $2,788,059.18. The trade was a 4.93% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Fady Ibraham Malik sold 2,000 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $45.98, for a total transaction of $91,960.00. Following the completion of the transaction, the executive vice president now directly owns 116,071 shares of the company’s stock, valued at $5,336,944.58. This trade represents a 1.69% decrease in their position. The disclosure for this sale can be found here. Insiders sold 96,816 shares of company stock valued at $3,942,345 in the last quarter. Company insiders own 2.70% of the company’s stock.

Wall Street Analysts Forecast Growth

CYTK has been the topic of several recent analyst reports. Stifel Nicolaus initiated coverage on Cytokinetics in a report on Wednesday, January 22nd. They issued a “buy” rating and a $80.00 target price on the stock. Cantor Fitzgerald upgraded shares of Cytokinetics to a “strong-buy” rating in a research report on Tuesday. Evercore ISI upgraded shares of Cytokinetics to a “strong-buy” rating in a research report on Friday, February 7th. Bank of America dropped their price objective on shares of Cytokinetics from $62.00 to $54.00 and set a “neutral” rating for the company in a research report on Tuesday, April 15th. Finally, Citigroup dropped their price objective on shares of Cytokinetics from $86.00 to $80.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Three equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Cytokinetics has an average rating of “Moderate Buy” and an average target price of $74.44.

Cytokinetics Stock Performance

Shares of Cytokinetics stock opened at $31.00 on Friday. The firm has a fifty day moving average of $38.88 and a two-hundred day moving average of $45.27. The stock has a market capitalization of $3.70 billion, a price-to-earnings ratio of -5.76 and a beta of 0.81. Cytokinetics, Incorporated has a 52 week low of $29.31 and a 52 week high of $61.40. The company has a debt-to-equity ratio of 5.93, a quick ratio of 9.28 and a current ratio of 9.28.

Cytokinetics (NASDAQ:CYTK) last issued its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.36) EPS for the quarter, beating the consensus estimate of ($1.41) by $0.05. The business had revenue of $1.60 million for the quarter, compared to the consensus estimate of $2.77 million. The business’s revenue was up 89.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.33) EPS. As a group, equities research analysts predict that Cytokinetics, Incorporated will post -5.24 EPS for the current year.

Cytokinetics Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.